Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review
Authors' conclusion
The literature evaluating adalimumab and other TNFi discontinuation, flare rates, and recapture success within the inflammatory arthritis population demonstrated less flare when medications were tapered, over abrupt stop in the RA, spondyloarthropathy, and JIA populations.
Study context
- Population
- Patients with well-controlled chronic inflammatory arthritides (rheumatoid arthritis (RA), AS, PsA, juvenile idiopathic arthritis (JIA)); publications 2000–2023
- Participants
- 49 studies
- Comparison
- Tapering vs abrupt stop of adalimumab and other tumor necrosis factor inhibitors (TNFi)
- Outcome
- Flare and recapture after adalimumab/TNFi discontinuation
Methodological detailssystematic search and review
- Systematic search and review
Pooled result
As reported in the abstract
- RA (32 studies, 8 RCTs): flare rates
- 33-87%
- RA: successful recapture generally high
- 80-100%
- Spondyloarthropathy: high recapture rates
- ≈90%
- JIA (5 observational studies): flare rates with tapering
- 17-63%
- JIA: flare rates with abrupt stopping
- 28-82%
Original publication
Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review. Pediatr Rheumatol Online J. Published 30 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →